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Abstract
Background: Application of genetically modified hematopoietic stem cells is increasingly mooted as a clinically
relevant approach to protein replacement therapy, immune tolerance induction or conditions where both
outcomes may be helpful. Hematopoietic stem and progenitor cell (HSPC)-mediated gene therapy often requires
highly toxic pretransfer recipient conditioning to provide a ‘niche’ so that transferred HSPCs can engraft effectively
and to prevent immune rejection of neoantigen-expressing engineered HSPCs. For widespread clinical application,
reducing conditioning toxicity is an important requirement, but reduced conditioning can render neoantigen-
expressing bone marrow (BM) and HSC susceptible to immune rejection if immunity is retained.
Methods: BM or HSPC-expressing OVA ubiquitously (actin.OVA) or targeted to MHC II+ cells was transferred using
low-dose (300 cGy) total body irradiation. Recipients were administered rapamycin, cyclosporine or vehicle for
3 weeks commencing at BM transfer. Engraftment was determined using CD45 congenic donors and recipients.
Induction of T-cell tolerance was tested by immunising recipients and analysing in-vivo cytotoxic T-lymphocyte
(CTL) activity. The effect of rapamycin on transient effector function during tolerance induction was tested using an
established model of tolerance induction where antigen is targeted to dendritic cells.
Results: Immune rejection of neoantigen-expressing BM and HSPCs after low-dose irradiation was prevented by a
short course of rapamycin, but not cyclosporine, treatment. Whereas transient T-cell tolerance developed in
recipients of OVA-expressing BM administered vehicle, only when engraftment of neoantigen-expressing BM was
facilitated with rapamycin treatment did stable, long-lasting T-cell tolerance develop. Rapamycin inhibited transient
effector function development during tolerance induction and inhibited development of CTL activity in recipients
of OVA-expressing BM.
Conclusions: Rapamycin acts to suppress acquisition of transient T-cell effector function during peripheral
tolerance induction elicited by HSPC-encoded antigen. By facilitating engraftment, short-course rapamycin permits
development of long-term stable T-cell tolerance.
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Background
Gene therapy approaches employing genetically modi-
fied hematopoietic stem and progenitor cells (HSPCs)
show great promise for expression of therapeutic pro-
teins within the hematopoietic system. Notable clin-
ical successes have been achieved with therapy of
severe combined immunodeficiency (scid)-X1 [1],
leukodystrophies [2, 3] and Wiskott–Aldrich syn-
drome [4]. Potential applications tested in preclinical
models are more diverse, encompassing a range of
blood disorders including hemophilia and sickle-cell
disease [5] and immunological disorders [6].
Enforced expression of antigen either ubiquitously or
targeted to antigen-presenting cells (APC) of the im-
mune system is a robust approach to inducing immune
tolerance which prevents priming of T-cell and B-cell re-
sponses to expressed proteins [7, 8]. This has the power
to prevent development of autoimmune disease in elic-
ited and spontaneous models leading to proposals for
therapeutic application [9, 10]. Indeed, under certain
conditions established memory T-cell responses can be
turned off [11], suggesting that enforced antigen expres-
sion may provide unique opportunities to control other-
wise difficult-to-treat memory T-cell responses. For
therapeutic application, an efficient means to achieve
de-novo enforced antigen expression is HSPC-based
gene therapy [12].
A critical requirement for clinical application of
HSPC-based gene therapies, particularly if intended
for therapy of nonlife-threatening diseases, is to min-
imise the toxicity of procedures associated with HSPC
transfer. Currently for HSPC-mediated gene therapies,
highly toxic pretransplant conditioning that both mye-
loablates and immunoablates patients prior to HSPC
transfer is typically used [3, 4]. This facilitates high
levels of engraftment of transferred HSPCs along with
substantial replacement of recipient hematopoietic
cells with those derived from the transferred, engi-
neered HSPCs respectively. In some disorders, such
as those where substantial replacement of long-lived
hematopoietically derived cells might be required,
immunoablation may be advantageous [4, 13], but
may not be required in, for example, scid, where pro-
geny of engineered HSPCs have a competitive advan-
tage and could more easily repopulate recipients [1].
In other disorders where large-scale replacement of
immune cells is not required, immunoablation is disad-
vantageous because it would be preferable to preserve
existing protective immunity. However, depending on
the approach used for directing expression of thera-
peutic proteins, preserving recipient immunity renders
transferred gene-engineered HSPCs susceptible to im-
mune attack [14] and failure of engraftment if they
express neoantigens as a result of engineering. This is
of relevance for both protein replacement therapies
and approaches for instatement of immune tolerance,
for example.
Previously we showed that one approach to limiting
immune attack and preserving the integrity of trans-
ferred gene-engineered bone marrow (BM) and HSPCs
was to restrict neoantigen expression to differentiated
leukocytes, away from engrafting HSPCs [15]. Ubiqui-
tous or ‘off-target’ expression of neoantigens in BM or
HSC leads to their destruction in recipients with intact
immunity [15, 16]. An alternative approach may be to
limit the development of immune responses in HSPC
recipients.
Here we continue to explore avenues to overcome
immune resistance to engraftment of neoantigen-
expressing gene-engineered HSPCs. Rapamycin is an
immunosuppressant that functions by inhibiting mam-
malian target of rapamycin (mTOR) to block entry of
T cells into the cell cycle which, unlike the calcine-
urin inhibitors cyclosporine and tacrolimus, does not
inhibit TCR-induced Ca2+ signaling [17, 18], which is
important for tolerance induction in some conditions
[19, 20]. Both clinical and preclinical studies indicate
that rapamycin is ‘tolerance-permissive’ in organ allo-
graft and other settings, whereas cyclosporine and ta-
crolimus may inhibit the development of immune
tolerance [21]. We report that a short course of rapa-
mycin treatment is sufficient to prevent immune re-
jection of neoantigen-expressing BM and HSPCs in
recipients with intact immunity. Protection of engraft-
ing cells is mediated by suppression of transient ef-
fector differentiation in T cells undergoing peripheral




OT-I, 11c.OVA, MII.OVA and actin.OVA mice have
been described elsewhere [7, 22–24]. Mice were main-
tained under specific pathogen-free conditions in the TRI
Biological Resources Facilities, Brisbane, Australia. Non-
transgenic C57BL/6 and B6.SJL-PtprcaPep3b/BoyJArc
(B6.SJL) mice were purchased from ARC (Perth,
Australia). Unless stated otherwise, in BM transplant ex-
periments recipient mice were B6.SJL (CD45.1+) and do-
nors were MII.OVA (CD45.2+), actin.OVA (CD45.2+) or
nontransgenic (non-Tg) C57BL/6JArc (all CD45.2+) mice.
To generate CD45.1+/CD45.2+ OT-I mice, B6.SJL mice
were crossed with OT-I mice. All animal procedures were
performed in accordance with the Australian Code for the
Care and Use of Animals for Scientific Purposes and ap-
proved by the University of Queensland Animal Ethics
Committee (projects DI/208/12; UQDI/296/14).
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Bone marrow and HPC transplantation
Donor mice were euthanised by CO2 narcosis and fe-
murs and tibias collected into mouse tonicity (MT)-PBS.
Bone marrow was flushed with MT-PBS/2.5% FCS,
erythrocytes lysed (NH4Cl/TRIS buffer) and BM washed
twice (MT-PBS/2.5% FCS). BM was resuspended in MT-
PBS and injected i.v. (lateral tail vein) within 3 hours of
total body irradiation (TBI; 300 cGy, 137Cs source). Un-
less stated otherwise, 10 × 106 bulk BM was transferred.
For high-dose irradiation experiments, the irradiation
was delivered as two equal doses (550 cGy) 3 hours
apart and mice were administered neomycin (1 mg/ml)
in drinking water for 3 weeks. HSPCs were prepared by
high-speed FACS sorting of lin–ve/c-kit+ve cells to typic-
ally >95% purity from bulk BM. HSPC-depleted BM was
lin+ve/c-kit–ve cells prepared from BM by high-speed cell
sorting.
Immunosuppressant administration
Rapamycin (Rapamune, Wyeth Australia) was diluted in
PBS and administered (0.6 mg/kg) by i.p. injection.
Cyclosporine (Sandimmune, Novartis Pharmaceuticals
Australia) was diluted in PBS and administered (25 mg/
kg) daily by i.p. injection. Immunosuppressant adminis-
tration commenced on the day of BM/HSPC transfer
and continued daily for the following 21 days unless the
experiment finished sooner. To determine the blood
concentration of rapamycin, whole blood was collected
in 0.5 M EDTA immediately prior to rapamycin admin-
istration on the days indicated and stored at −30 °C. LC-
MS/MS analysis was performed using an Alliance HT
LC system interfaced to a Quattro-Premier mass spec-
trometer (Waters Corporation, Milford, MA, USA).
In-vitro and in-vivo assays
OVA/QuilA immunisation was as described previously
[23]. Intracellular cytokine staining and in-vivo CTL
assays were performed as described previously [7].
CFSE labeling was performed as described elsewhere
[7] and proliferation indices calculated as described
previously [25].
Flow cytometry
Sample preparation for flow cytometry of BM, spleen
and pooled lymph node (axillary, brachial, inguinal
and mesenteric) was as described previously [7]. mAb
were purchased from Biolegend, BD Biosciences and
BioXcell (Lebanon, NH, USA) or were grown, purified
and conjugated in-house. Analysis of peripheral blood
for engraftment determination was performed using a
bead-based counting assay as described previously
[26]. Cytometric data were acquired using BD Canto
or BD LSRII cytometers and analysed using Diva
(BD) or Flow-Jo (Tree-Star) software.
Statistical analysis
Student’s t test (two-tailed) was used for comparison of
means and one-way ANOVA with Newman–Keuls or
Tukey’s post test for multiple comparisons (GraphPad
Prism 5 or Prism 6). p < 0.05 was considered significant.
Results
Increasing the dose of cells injected partially overcomes
immune resistance to gene-modified BM
Transfer of large doses of BM promotes engraftment
of nonimmunogenic BM [27]. We tested whether in-
creasing the dose of transferred immunogenic BM
could overcome immune-mediated resistance to en-
graftment under conditions of low-dose irradiation
where immune function is largely preserved [15].
Increasing the dose of BM transferred two-fold or
five-fold over that normally transferred (107 cells, ap-
proximately 106 HSPCs/kg) led to a dose-dependent
increase in donor-type leukocyte accumulation 2 weeks
after BM transfer but this did not necessarily predict
the final outcome with relation to long-term engraft-
ment (Fig. 1a). Overall, however, increasing the dose
of BM cells transferred increased the proportion of
mice in which engraftment was successful (Fig. 1a, b),
although engraftment was not observed in all recipi-
ents. Therefore, increasing the number of BM cells
transferred, even to a ‘mega-dose’, did not reliably
overcome immune resistance. While the trend sug-
gested that further increases in BM dose may have
led to engraftment in a higher proportion of recipi-
ents (Fig. 1a, b), this would be impractical for any-
thing other than laboratory studies and unlikely to
translate to a clinical scenario.
Short-course rapamycin treatment permits engraftment
of neoantigen-expressing BM under immune-retaining
conditioning
We next tested alternative approaches to achieving ef-
fective engraftment of neoantigen-expressing, im-
munogenic gene-modified BM under low-dose
irradiation. For this we chose a short, 3-week course
of treatment with rapamycin or cyclosporine and
compared engraftment of BM carrying transgenes en-
coding OVA expressed ubiquitously (actin.OVA) or in
MHC class II+ cells (MII.OVA) where transient ex-
pression of MHC II, and consequently the OVA
transgene, in HSC leads to failure of engraftment due
to immune rejection. Addition of rapamycin pro-
moted engraftment of both actin.OVA and MII.OVA
BM, and donor-derived hematopoiesis was sustained
for at least 6 months after transfer (Fig. 1c). Accumu-
lation of donor-derived myeloid cells and DC was
rapid and these populations accumulated to close to
their final levels within 2–3 weeks of transfer (Fig. 1d,
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Fig. 1 (See legend on next page.)
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e). Donor-derived B-cell populations established more
slowly but to higher levels overall, and T-cell popula-
tions stabilised slowly (Fig. 1f–h). Examination
26 weeks after transfer indicated accumulation of
donor-derived leukocytes in peripheral blood leuko-
cytes (PBL) reflected that lymphoid tissues (Fig. 1i)
and examination of lin–ve,c-kit+ HSPC in BM (Fig. 1j)
showed that accumulation of donor-derived leukocytes
in the periphery reflected engraftment of donor-
derived cells in the hematopoietic stem and progeni-
tor cell compartment. In comparison with rapamycin,
cyclosporine was much less effective and engraftment
failed in 50% of MII.OVA BM recipients (Fig. 2a, b).
Rapamycin promotes engraftment by limiting immune
rejection
As shown in Fig. 1 controlling immune pressure by
administration of rapamycin allows MII.OVA BM to
engraft stably, but at a consistently reduced level
compared with non-Tg or actin.OVA BM (Fig. 1c–j).
This likely reflects reduced engraftment capacity of
MII.OVA HSC [15] but could also potentially reflect
transgene expression-induced endoplasmic reticulum
(ER) stress [28] that might be relieved by rapamycin.
Therefore, we tested the effect of rapamycin on the
fitness of MII.OVA and actin.OVA BM in a competi-
tive repopulation assay. Because recipient immunity is
ablated by the lethal irradiation used, nonimmune ef-
fects of rapamycin are tested. When equal numbers
of actin.OVA and non-Tg control or MII.OVA and
non-Tg control BM were mixed and transferred to
high-dose (1100 cGy) irradiated mice, MII.OVA BM
showed a deficit compared with actin.OVA BM in
leukocyte accumulation and engraftment in the HSPC
compartment in PBS-treated controls (Fig. 2c, d) as
expected (Fig. 1 [15]), consistent with reduced
hematopoietic capacity. Notably, administration of
rapamycin did not alter the relative pattern of donor-
type leukocyte development in or between recipient
groups (Fig. 2c, d), indicating that rapamycin did not
provide a competitive advantage specific for MII.OVA
engraftment and hematopoiesis in the absence of im-
mune pressure.
Antigen-expressing BM transfer paradoxically induces
both BM rejection and transient T-cell unresponsiveness
to BM-expressed antigen in the absence of rapamycin
We reported previously that tolerance induction by
antigen-encoding BM transfer requires establishment of
stable engraftment. Therefore, we next tested whether
enabling engraftment of antigen-expressing BM with a
(See figure on previous page.)
Fig. 1 Rapamycin administration enables long-term multilineage engraftment of antigen-encoding BM under immune-preserving conditions. a, b
Titrated doses of MII.OVA BM (5 × 106, 107, 2 × 107 and 5 × 107 cells) mice were transferred i.v. to B6.SJL mice under low-dose (300 cGy) irradiation.
At designated time-points, engraftment was determined in peripheral blood leukocytes (PBL) by flow cytometry. c–j BM (107 cells) from non-Tg,
MII.OVA and actin.OVA mice was transferred i.v. to B6.SJL mice under low-dose irradiation (300 cGy TBI). Rapamycin or PBS was administered i.p.
for 22 days commencing at BM transfer. Engraftment was determined for total leukocytes (c) or leukocyte subsets (d–h) within PBL at the indicated
time-points and for total leukocytes in the spleen (i) and lin–ve/sca-1+ve/c-kit+ve HSPC) in BM (j) 26 weeks after BMT. Data show individual mice or mean
± SEM of results from a single experiment (a, b), mean ± SEM of results pooled from three or four experiments (c–h) or individual mice with mean ±
SEM pooled from three or four experiments (i, j). ANOVA with Tukey’s post test. BM bone marrow, BMT bone marrow transplant, HPC lin–ve/sca-1+ve
/c-kit+ve HSPC
Fig. 2 Rapamycin inhibits development of anti-graft immunity. a, b BM
(107 cells) from MII.OVA mice was transferred i.v. to B6.SJL mice under
low-dose irradiation (300 cGy TBI). Rapamycin (rapa), cyclosporine (CyA)
where indicated or PBS was administered i.p. for 22 days commencing
at BM transfer as indicated and mice were studied in parallel. Engraft-
ment was determined within PBL at the time-points indicated (a) and in
the spleen 5 or 6 weeks after BMT (b). Data are individual mice (a) with
mean ± SEM (b) pooled from two separate experiments. c, d Recipient
mice (C57BL/6, CD45.2+) were irradiated (1100 cGy) and a 1:1 mixture of
nontransgenic (B6.SJL; CD45.1+) and MII.OVA (CD45.2+) or nontransgenic
(B6.SJL; CD45.1+) and actin.OVA (CD45.2+) mice transferred i.v. Mice were
administered rapamycin (0.6 mg/kg) or PBS i.p. for 22 days commencing
at BM transfer (BMT). Six weeks after BMT, relative accumulation
of donor leukocytes in the spleen (c) and donor HSPCs in BM
were determined (d). Data are from a single experiment representative
of two performed where the effect of rapamycin was similar but overall
engraftment differed. Data show individual mice with mean ± SEM.
ANOVA with Tukey’s post test. BM bone marrow
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short course of rapamycin treatment promoted tolerance
induction. We transferred BM using low-dose irradi-
ation, where there is retention of immunity in recipients,
with or without rapamycin administration. Four weeks
after BM transfer, to determine antigen-responsiveness,
mice that received BM were sham-immunised or immu-
nised with OVA/QuilA and 1 week later an OVA-
specific in-vivo CTL assay performed. CTL activity was
compared with immunised but unirradiated, no BMT
controls analysed in parallel. Recipients of non-Tg BM
when immunised mounted significant CTL activity
against OVA257–264-loaded targets which did not differ
significantly from unirradiated, no BMT controls
(Fig. 3a), indicating substantial immune responsiveness.
Although rapamycin-treated non-Tg BM recipients gen-
erally showed induction of CTL activity in response to
immunisation, this was reduced compared with their
PBS-treated counterparts, indicating that rapamycin ad-
ministration somewhat inhibited the development of
CTL activity in BM recipients. Interestingly, rapamycin
inhibition of CTL induction relative to PBS controls oc-
curred only in irradiated mice and not in unirradiated,
no BMT controls (Fig. 3a). Recipients of MII.OVA or
actin.OVA BM, when immunised, developed little OVA-
specific CTL activity regardless of whether they had
been administered rapamycin or not. This was surprising
because, in the absence of rapamycin, MII.OVA and
actin.OVA BM fails to engraft, suggesting that in the ab-
sence of rapamycin treatment there is induction of anti-
graft immunity, but unresponsiveness also develops. In-
hibition of CTL induction in rapamycin-treated
MII.OVA and actin.OVA BM recipients is consistent
with induction of tolerance in the presence of successful
antigen-encoding BM engraftment [15] but could poten-
tially also reflect a compound effect of OVA-encoding
BM engraftment and rapamycin treatment. In contrast,
the failure of CTL induction in recipients of OVA-
encoding/expressing BM that were not administered
rapamycin could reflect several effects.
Stable long-term tolerance to BM-expressed antigen requires
rapamycin-facilitated engraftment
Before investigating the mechanisms that might underlie
failure of CTL induction 4 weeks after BM transfer, we
wished to determine firstly whether unresponsiveness
was transient, indicating a peri-BMT effect, or whether
unresponsiveness to OVA was long-lasting irrespective
of rapamycin administration. To achieve this we per-
formed BM transfers, but waited 25 weeks before mice
were sham-immunised or immunised with OVA/QuilA
and then OVA-specific in-vivo CTL activity was tested
1 week later. In this setting, in recipients of non-Tg BM
regardless of rapamycin treatment there was strong CTL
activity, equivalent to that in no BMT controls, induced
by immunisation. In MII.OVA BM recipients, immunisa-
tion elicited CTL activity only in PBS-treated but not
rapamycin-treated recipients (Fig. 3b). A similar trend
was observed in the small number of actin.OVA BM re-
cipients analysed (Fig. 3b); however, this was not signifi-
cant in the PBS-treated group due to the low number of
mice tested. In contrast, in rapamycin-treated recipients
of MII.OVA and actin.OVA BM, CTL induction by im-
munisation was almost completely damped (Fig. 3b).
This demonstrates that although there was modulation
of OVA responsiveness soon after BMT in recipients of
OVA-encoding BM regardless of rapamycin treatment,
stable, long-lasting T-cell tolerance only occurred when
OVA-expressing BMT was combined with rapamycin to
facilitate stable engraftment of OVA-expressing BM.
Rapamycin treatment delays T-cell recovery after BMT
To investigate why OVA responsiveness may have been
modulated soon after BMT in rapamycin-treated non-Tg
BM recipients and perhaps in OVA-encoding BM recipi-
ents, we first determined whether residual rapamycin
may play a role. The rapamycin concentration in whole
blood was within the clinical therapeutic range (6–
15 μg/l) in most mice throughout the treatment period
but had diminished to undetectable levels 7 days after
cessation of treatment (Fig. 3c) when mice in some ex-
periments mice were immunised. Examination of the T-
cell repopulation kinetics after irradiation showed that
rapamycin administration delayed recovery of CD8+ and
CD4+ T-cell populations from the partial lymphopenia
induced by low-dose irradiation (Fig. 3d, e). This was
most prominent during or soon after cessation of rapa-
mycin treatment (Fig. 3d, e). By 5 weeks after rapamycin
cessation, T-cell recovery was approximately equal in all
groups. This suggests that rapamycin-treated recipients
of non-Tg BM exhibit impaired antigen-responsiveness
due to reduced T-cell repopulation. However, this re-
flects total CD8+ or CD4+ T-cell number and does not
necessarily indicate relative repopulation with OVA-
specific T cells or OVA responsiveness specifically, nor
explain why PBS-treated recipients of OVA-encoding/
expressing BM exhibit CTL unresponsiveness 4–5 weeks
after BMT. When the presence of CD4+CD25+FoxP3+
regulatory T cells (Treg) was analysed, we found no evi-
dence that Treg were preferentially expanded in any
group, suggesting that Treg were not responsible for the
unresponsiveness observed.
Development of stable long-term tolerance engraft is as-
sociated with the extended presence of cognate antigen
It has been proposed that maintenance of T-cell toler-
ance requires stable engraftment of transferred HSPCs
in order that a long-term source of ongoing tolerogenic
antigen is generated [15]. We sought to determine
Bhatt et al. Stem Cell Research & Therapy  (2017) 8:57 Page 6 of 13
whether this might underlie the effectiveness of transient
rapamycin administration. To probe for the presence of
OVA, CFSE-labeled OT-I T cells were transferred
5 weeks after transfer of non-Tg or MII.OVA BM with
or without rapamycin treatment and CFSE dilution de-
termined 3 days later. In recipients of MII.OVA BM,
CFSE dilution in OT-I T cells (Fig. 4a, b) indicated that
OVA-specific T cells recognised their cognate antigen re-
gardless of whether recipients had been treated with
rapamycin or not. However, the extent of cell division
was substantially greater and more uniform in MII.OVA
BM recipients if treated with rapamycin (Fig. 4a, b), con-
sistent with the higher levels of donor-type leukocyte de-
velopment relative to their PBS-treated counterparts
(Fig. 4c). When similar assays were performed 26 weeks
after BMT, OT-I division indicated the presence of im-
munologically relevant OVA in MII.OVA BM recipients
that had been transiently administered rapamycin at the
time of BM transfer, but not in the PBS-treated counter-
parts (Fig. 4d), in keeping with the stable engraftment
observed in rapamycin-treated recipients (Fig. 1). This
indicated that immunologically relevant OVA was
present only transiently in PBS-treated MII.OVA BM
recipients.
OVA arises from transferred HSPCs in MII.OVA BM
recipients
Paradoxically, in the absence of rapamycin, transfer of
OVA-expressing BM induces not only transient toler-
ance but also promotes the ultimate rejection of engraft-
ing HSPCs. It is possible that this unresponsiveness is
due to transient expression of OVA in PBS-treated re-
cipients of OVA-expressing BM because immunologic-
ally active OVA is not present 26 weeks after BMT
(Fig. 4a, d). Because cells within the transferred whole
BM prepared from MII.OVA donors express OVA [15]
and could potentially induce tolerance or immunity [29],
Fig. 3 Stable engraftment is required for long-term tolerance. a–e BM
(107 cells) from non-Tg, MII.OVA and actin.OVA mice was transferred i.v.
to B6.SJL mice under low-dose irradiation (300 cGy TBI). Rapamycin
(rapa) or PBS was administered i.p. for 22 days commencing at BM
transfer (BMT). Four weeks (a) or 25 weeks (b) after BMT, mice were
sham (PBS/QuilA) or OVA (OVA/QuilA) immunised. Age-matched,
unirradiated and untransplanted mice were immunised and analysed
in parallel. One week later an in-vivo CTL assay was performed. Blood
was collected at the indicated time-points and whole blood rapamycin
concentration determined by HPLC (c). CD8+ (d) and CD4+ (e) T cells
were enumerated in blood by flow cytometry. Data are pooled from
three or four experiments and show individual mice with mean ± SEM
(a, b), pooled from two experiments where mice from all experimental
groups were pooled at each time-point and show individual mice with
mean ± SEM (c) or pooled from three or four experiments and depict
mean ± SEM (n = 8/group). ANOVA with Tukey’s post test. *PBS > rapa
(p < 0.05), **PBS > rapa (p < 0.01 or greater), ***PBS > rapa (p < 0.001
or greater)
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we next determined whether the immunologically rele-
vant OVA present in PBS-treated MII.OVA BM recipi-
ents that might have contributed to induction of
rejection and the development of unresponsiveness to
OVA was derived from the BM graft, HSPCs within the
graft or from the non-HSPC component of the graft.
Whole BM, HSPCs or HSPC-depleted BM from
MII.OVA and BM from non-Tg mice was transferred to
low-dose irradiated recipients with or without rapamycin
treatment and 4 weeks after BMT CFSE-labeled OT-I T
cells were transferred to detect the presence of immuno-
logically relevant OVA. OT-I proliferated only in recipients
of MII.OVA whole BM or HSPCs and not HSPC-depleted
BM (Fig. 4d). This suggests the source of OVA in
MII.OVA BM recipients was HSPCs, most likely
through engraftment and/or development of progeny
(Fig. 1). Based on the reduced proliferation of OT-I T
cells at week 5 (Fig. 4b) relative to week 4 (Fig. 4e),
residual OVA is cleared quickly after engraftment fail-
ure in PBS-treated recipients.
Rapamycin inhibits development of transient effector
function during tolerance induction
In vivo, T cells fated for peripheral tolerance induction
undergo a period of abortive proliferation followed by a
period of population contraction during which most
antigen-specific T cells are deleted. Significantly, during
the expansion phase T cells transiently exert some de-
gree of effector function [23, 30, 31]. Therefore, we ex-
plored the effects of rapamycin using a well-defined
mouse model of tolerance in which OVA is expressed
tolerogenically by DC (11c.OVA mice) and where the
development of transient effector function by CD8+ T
Fig. 4 Presence of antigen after transfer of MII.OVA bone marrow
induces transient antigen specific tolerance. a–c BM (107 cells) from
non-Tg and MII.OVA mice was transferred i.v. to B6.SJL mice under
low-dose irradiation (300 cGy TBI). Rapamycin (rapa; 0.6 mg/kg) or
PBS was administered i.p. for 22 days commencing at BMT. Five or
26 weeks after BMT, CFSE-labeled OT-I T cells (5 × 106) cells were
transferred i.v. and 3 days later CFSE dilution determined by flow cy-
tometry of lymph node cells. Data show representative histograms
and proliferation index (mean ± SEM) for OT-I in pooled lymph
nodes from each group (a) or individual mice at 5 weeks where bars
denote mean ± SEM (b) and the level of engraftment in the spleen
for individual mice where bars denote mean ± SEM (c) or at 26 weeks
(d). Pooled from two experiments with 2 mice per group (5 weeks)
or from a single experiment with 2 mice per group (26 weeks). e, f
Whole BM, HPC (Lin–ve,c-kit+; 2 × 105 cells) and HPC-depleted BM
(Lin+ve,c-kit–; 107 cells from non-transgenic or MII.OVA mice was
transferred to B6.SJL (CD45.1+) mice under low-dose irradiation. Four
weeks after BMT, CFSE-labeled OT-I T cells (5 × 106) were transferred
i.v. and 3 days later CFSE dilution determined by flow cytometry.
Data show proliferation index of OT-I cells (e) and engraftment levels
in the spleens of individual mice (f) pooled from two experiments. Bars
denote mean ± SEM. ANOVA with Tukey’s post test. BM bone marrow,
HPC defines lin–ve/c-kit+ve hematopoietic progenitor cells
Bhatt et al. Stem Cell Research & Therapy  (2017) 8:57 Page 8 of 13
cells undergoing is well characterised [7, 23]. In this set-
ting, 3 days after transfer into the tolerogenic 11c.OVA
environment, OVA-specific CD8+ OT-I T cells had pro-
liferated and expanded substantially in control PBS-
treated mice compared with non-Tg controls (Fig. 5a).
Furthermore, a large proportion of the OT-I population
in the tolerogenic 11c.OVA environment produced IFN-
γ as an indicator of transient effector differentiation
(Fig. 5b). Administration of rapamycin significantly re-
duced expansion of OT-I T cells in 11c.OVA recipients
(Fig. 5a) and inhibited effector differentiation indicated
by reduced acquisition of IFN-γ production (Fig. 5b)
when analysed 3 days after OT-I transfer. Rapamycin ad-
ministration strikingly reduced the total number of IFN-
γ+ve (effector-differentiated) OT-I T cells present in the
11c.OVA recipients 3 days after transfer (Fig. 5c). In
contrast, administration of cyclosporine in this setting
limited IFN-γ production but had weaker effects on ex-
pansion of OT-I T cells such that the total number of
IFN-γ+ve (effector-differentiated) OT-I T cells was not
significantly reduced. This difference between rapamycin
and cyclosporine was maintained at least to 7 days after
transfer (Fig 5d–f ).
To identify whether the action of rapamycin was to in-
hibit differentiation of effector function in the ‘intrinsic-
ally tolerogenic’ MII.OVA BM transfer setting, non-Tg
or MII.OVA BM was transferred to low-dose (300 cGy)
irradiated recipients with or without rapamycin adminis-
tration, and spontaneous CTL activity that had devel-
oped 17 days later, when BM rejection has commenced
(Fig. 1, Additional file 1) and engraftment is failing
(Fig. 4c), was tested. No CTL activity was detected in re-
cipients of non-Tg BM as expected (Fig. 5g). In contrast,
in PBS-treated MII.OVA BM recipients, substantial kill-
ing of OVA257–264-pulsed targets was observed, which
was not present in rapamycin-treated MII.OVA BM re-
cipients (Fig. 5g).
Rapamycin therefore acts to prevent the emergence of
the transient effector function elicited in OVA-specific T
cells as a component of tolerance induction. Ironically,
engraftment appears to proceed initially giving rise to
donor-derived antigen expressing DC (Additional file 1)
and while these are potentially tolerogenic, the transient
effector function elicited in the early phase of tolerance
induction leads to rejection of antigen-expressing HSC.
In the absence of transient immune suppression to con-
trol this, engraftment fails and induction of long-term
tolerance that requires ongoing antigen expression by
the progeny of successfully engrafted OVA-encoding
HSPCs stalls before fully developing.
Discussion
Increasing the clinical applicability of HSPC-based gene
therapy is an important goal that will maximise the
usefulness of this potentially powerful therapeutic. De-
fining approaches that reduce the toxicity of HSPC
transfer-associated procedures is a key requirement. En-
abling high levels of engineered HSPC engraftment and
subsequent leukocyte development through either in-
creasing the competitive advantage of transferred engi-
neered HSPCs or opening ‘engraftment niches’ in the
recipient whilst reducing treatment toxicity is one im-
portant focus. However, here we have focused on over-
coming the challenges of immune resistance that is a
consequence of attempts to achieve the desired outcome
of preserving recipient immune function during HSPC-
mediated gene transfer. Here we show that HSPC-based
approaches capable of inducing immune tolerance which
could, for instance, alleviate autoimmune diseases or al-
lergies can be hindered by the development of transient
effector function in the very T cells that are targeted for
inactivation by the procedure. Development of transient
effector function is a normal component of the early
phase of tolerance induction in T cells [23, 30, 31] but,
using rapamycin, we show this can be readily controlled
by a short course of appropriate immunosuppressant ad-
ministration. Limiting effector differentiation during
the critical peritransfer period facilitates engraftment
and leads to establishment of long-term tolerance that
does not require additional immunosuppression for
maintenance.
A notable observation was that rapamycin was highly
effective at promoting engraftment of BM expressing a
neoantigen under the immune-preserving conditions
used, but that cyclosporine was much less effective. This
is supported by similar results in an allogeneic BM
transplant setting [32]. Competitive repopulation assays
ruled out that rapamycin provided a nonimmunological
engraftment-enhancing effect to transgene-encoding
HSPCs. While rapamycin did not appear to act on
HSPCs, agents that protect the HSPC niche from
radiation-induced damage or foster hematopoiesis or
myelopoiesis/erythropoiesis, such as lysophophatidic
acid [33, 34], might promote post-HSPC transfer en-
graftment. Rapamycin or its analog everolimus has been
reported as ‘tolerance-permissive’ in organ allograft [21]
and other settings [35, 36], and it is possible that this
underlies these observations. Effectiveness here, how-
ever, appeared to be associated with the capacity of rapa-
mycin to inhibit both expansion and transient effector
function elicited by tolerogenic antigen presentation.
Cyclosporine, by contrast, poorly controlled expansion
of T cells undergoing tolerance induction. In a small
number of cyclosporine-treated animals tested, respon-
siveness to OVA was inversely correlated with the level
of MII.OVA BM engraftment present. This is in line
with previous conclusions that, under conditions where
potentially tolerogenic BM is transferred, tolerance is
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Fig. 5 Rapamycin inhibits T-cell effector differentiation during tolerance induction. a–g Naive OT-I cells were transferred to 11c.OVA mice and
rapamycin (rapa), cyclosporine (CyA) or PBS was administered 3 hrs before adoptive transfer and daily thereafter. Three days (a–c) or 7 days (d–f)
after OT-I transfer, spleens were harvested and OT-I cells enumerated in the spleen (a, d), the proportion of OT-I T cells producing IFN-γ
was determined by intracellular cytokine staining (b, e) and the total number of IFN-γ-producing OT-I T cells per spleen calculated (c, f)
were determined. g BM (107 cells) from non-Tg and MII.OVA mice was transferred i.v. to B6.SJL mice under low-dose irradiation (300 cGy
TBI). Rapamycin (0.6 mg/kg) or PBS was administered i.p. for 16 days commencing at BM transfer. The day after rapamycin cessation an
in-vivo CTL assay was performed. Data represent individual mice pooled from two experiments (mean ± SEM). ANOVA with Tukey’s post
test. BM bone marrow
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related to successful engraftment [15] rather than per-
haps the immunosuppressant used. It might be that the
effectiveness of rapamycin as an anti-proliferative agent
for T cells [37] is the critical factor, particularly here
where tolerogenic rather than immunogenic antigen
presentation is present. The anti-proliferative effects of
rapamycin impaired T-cell recovery after irradiation and
BM transfer, and this could potentially also contribute.
Interestingly, the extent of the rapamycin-induced delay
in T-cell reconstitution differed somewhat between CD8
+ and CD4+ T cells. Why CD4+ T cells appear to be
more affected remains unclear. However, a possible ex-
planation is that the homeostatic proliferation which
contributes to T-cell recovery after low-dose irradiation
[38] is modulated by the differential sensitivity of distinct
homeostatic cytokines such as IL-7 and IL-15 to
rapamycin-mediated inhibition of mTOR between differ-
ent T-cell subsets [39–41].
Moderate doses of irradiation can lead to BM transfer-
associated regulatory T cell (Treg) expansion [42] which
could potentially be enhanced by rapamycin. While not
shown, we found no evidence that Treg expansion con-
tributed to rapamycin-mediated effects. However, in
other studies the irradiation dose required for expansion
of antigen-specific CD4+CD25+FoxP3+ Treg was higher
(>450 cGy) [42] or myeloablative doses of irradiation
were used for CD8+Foxp3+ Treg induction/expansion
[43], and the latter study used an allogeneic transplant
setting and alloantigen was required for Treg gener-
ation/expansion. In other studies exploring transfer of
antigen-encoding BM, no evidence of Treg induction
has been reported [10] unless CD4+ TCR transgenic T
cells are included [44, 45]. Administration of rapamycin
has also been shown to induce or expand Treg in vivo,
but in many cases this has been in the presence of coad-
ministered antigen and/or a source of exogenous IL-2
[35, 36] and strong inflammatory signals may promote
this effect [46]. The rapamycin treatment period of
3 weeks chosen here was based on our previous studies
showing that induction of peripheral CD8+ T-cell toler-
ance is complete within 2–3 weeks of antigen encounter
[7] and, although not tested here, it is possible a shorter
course is also effective.
In the absence of rapamycin, engraftment and
leukocyte development is transient, proceeds for ap-
proximately 2 weeks, but ultimately fails (Fig. 1) due to
immune rejection. Paradoxically, despite immune rejec-
tion of OVA-encoding BM, OVA-specific CD8+ T cells
are either deleted or rendered antigen-unresponsive as
recipients fail to develop CTL activity in response to
immunisation for some time after BM rejection. We
conclude this is mediated by a transient presence of
HSPC-derived OVA manifesting in the absence of rapa-
mycin. However, once OVA is no longer present,
immune responsiveness recovers likely through thymic
export of OVA-specific T cells which is prevented by
central tolerance in the presence of stable OVA-
encoding BM engraftment. Whether HSPCs directly, or
their progeny or host APC, are responsible is yet to be
defined. It is also possible in this setting that the CTL
activity elicited against transferred HSPCs is integral to
tolerance induction by inducing apoptosis-mediated re-
lease of tolerogenic antigen as reported for CTL attack
of pancreatic islet β cells [47].
The transient effector state that occurs in T cells early
during tolerance induction [23, 30, 31] likely reflects a
partially differentiated state that occurs during periph-
eral tolerance induction while T cells are integrating en-
vironmental signals and the final cell is being
determined. The presence of transient T-cell effector
function during ‘tolerisation’ is likely of little conse-
quence under normal steady-state conditions because
only a small number of potentially pathogenic autoreac-
tive T cells would be undergoing tolerance induction at
any one time and the number of target cells would be
numerically much larger. Although immune preserving,
the conditioning used in the BM transfer setting tested
here results in partial lymphopenia which has the poten-
tial to promote the deleterious effects of the transient ef-
fector function elicited [48], and this may be particularly
evident when target cells, in this case engrafting HSPCs,
are present in low numbers. Under these circumstances,
controlling transient effector function appears critical
and rapamycin may be particularly effective through the
combined effects on proliferation and effector differenti-
ation discussed.
Our previous studies and those of others indicate that
long-lasting expression of BM-encoded antigen is crucial
to maintain tolerance [15, 49, 50]. Our data are consistent
with a conclusion that many cellular sources of antigen
are tolerogenic, but a critical window exists where the cel-
lular antigen sources require protection from transient ef-
fector T-cell attack to establish tolerance. Supporting this
there is emerging evidence in humans that a persistent
source of antigen maintains BM-induced tolerance,
although the source of antigen may not need to be BM-
derived cells [51]. Lessons learned here that transient im-
munosuppression, using appropriate tolerance-permissive
agents, provides a window of opportunity for tolerance in-
duction may be applicable to a range of gene-therapy set-
tings where immunity is preserved and the potential for
immune resistance to therapeutic proteins is generated.
Potential settings include limiting immune responses to
therapeutically expressed proteins, facilitating viral vector-
mediated gene transfer where the viral vector may be im-
munogenic approaches or preventing immune responses
to the products of genes edited using, for example,
CRISPR/Cas9 technologies.
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Conclusions
A short course of rapamycin promotes the engraftment
of gene-engineered, antigen-expressing BM by suppress-
ing the acquisition of transient T-cell effector function
during peripheral tolerance induction that is elicited by
HSPC-encoded antigen. By facilitating engraftment,
short-course rapamycin permits development of long-
term stable engraftment which maintains T-cell toler-
ance through a combination of central and peripheral
mechanisms. Such short-course treatment with conven-
tional immunosuppression represents a clinically applic-
able approach to overcoming immune resistance to
genetically engineered bone marrow when immune-
preserving conditions are employed.
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